Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson N Stone

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Brachytherapy|November 3, 2009
Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?Nelson N Stone, Jamie A Cesaretti, Barry Rosenstein, et al.
Urology|February 5, 2013
Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-upMichael Buckstein, Todd J Carpenter, Nelson N Stone, et al.
BJU International|June 19, 2013
The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomesRichard G Stock, Michael Buckstein, Jerry T Liu, et al.
Current Urology Reports|March 15, 2011
Update on prostate brachytherapy: long-term outcomes and treatment-related morbidityJohnny Kao, Jamie A Cesaretti, Nelson N Stone, et al.
Urologic Oncology|December 12, 2002
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancerSteven Lehrer, Nelson N Stone, Michael J Droller, et al.
Brachytherapy|April 6, 2004
What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptomsRichard G Stock, Nelson N Stone, Mehud Dahlal, et al.
International Journal of Radiation Oncology, Biology, Physics|September 13, 2006
Changing the patterns of failure for high-risk prostate cancer patients by optimizing local controlRichard G Stock, Alice Ho, Jamie A Cesaretti, et al.
BJU International|January 11, 2018
Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapyEmily Schlussel Markovic, Michael Buckstein, Nelson N Stone, et al.
International Journal of Radiation Oncology, Biology, Physics|July 28, 2009
Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomesNelson N Stone, Richard G Stock, Jamie A Cesaretti, et al.
Brachytherapy|July 19, 2008
Distant and local recurrence in patients with biochemical failure after prostate brachytherapyRichard G Stock, Jamie A Cesaretti, Pamela Unger, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Brachytherapy|November 3, 2009
Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?Nelson N Stone, Jamie A Cesaretti, Barry Rosenstein, et al.
Urology|February 5, 2013
Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-upMichael Buckstein, Todd J Carpenter, Nelson N Stone, et al.
BJU International|June 19, 2013
The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomesRichard G Stock, Michael Buckstein, Jerry T Liu, et al.
Current Urology Reports|March 15, 2011
Update on prostate brachytherapy: long-term outcomes and treatment-related morbidityJohnny Kao, Jamie A Cesaretti, Nelson N Stone, et al.
Urologic Oncology|December 12, 2002
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancerSteven Lehrer, Nelson N Stone, Michael J Droller, et al.
Brachytherapy|April 6, 2004
What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptomsRichard G Stock, Nelson N Stone, Mehud Dahlal, et al.
International Journal of Radiation Oncology, Biology, Physics|September 13, 2006
Changing the patterns of failure for high-risk prostate cancer patients by optimizing local controlRichard G Stock, Alice Ho, Jamie A Cesaretti, et al.
BJU International|January 11, 2018
Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapyEmily Schlussel Markovic, Michael Buckstein, Nelson N Stone, et al.
International Journal of Radiation Oncology, Biology, Physics|July 28, 2009
Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomesNelson N Stone, Richard G Stock, Jamie A Cesaretti, et al.
Brachytherapy|July 19, 2008
Distant and local recurrence in patients with biochemical failure after prostate brachytherapyRichard G Stock, Jamie A Cesaretti, Pamela Unger, et al.
Pageof 12